AI and Telemedicine for the Retina Specialist

<p>In this episode, I sit down with <strong>Kester Nahen, PhD,</strong> as we discuss the use of artificial intelligence and telemedicine among retina specialists. Nahen will also discuss Notal Vision’s ForseeHome device for monitoring and the company’s Home OCT artificial intelligence-enable platform for monitoring AMD.</p> <ul> <li>Intro <strong><em>:14</em></strong></li> <li>In this episode <strong><em>:21</em></strong></li> <li>About Dr. Nahen <strong><em>1:24</em></strong></li> <li>The interview <strong><em>1:42</em></strong></li> <li>The background of Kester Nahen <strong><em>2:00</em></strong></li> <li>Nahen’s thoughts on the current state of telemedicine and artificial intelligence <strong><em>5:10</em></strong></li> <li>Will artificial intelligence replace the clinical aspect of what we do? <strong><em>7:42</em></strong></li> <li>About Notal Vision’s ForseeHome Device <strong><em>9:30</em></strong></li> <li>The AMD criteria required for use of ForseeHome <strong><em>11:54</em></strong></li> <li>As a result of COVID-19, has there been an increased interest in using ForseeHome? <strong><em>13:15</em></strong></li> <li>What is the best way for ophthalmologists and eyecare providers to get more information about the ForseeHome program? <strong><em>14:40</em></strong></li> <li>More details on Notal Vision’s Home OCT and will it really change and revolutionize the way retina specialists monitor patients? <strong><em>16:00</em></strong></li> <li>What’s the status of the FDA approval process for the Home OCT? <strong><em>21:10</em></strong></li> <li>What does Nahen think is the most important topic facing the ophthalmology industry today and what will be in the future? <strong><em>23:05</em></strong></li> <li>Nahen’s final thoughts <strong><em>25:30</em></strong></li> </ul> <p><strong>Kester Nahen, PhD,</strong> is the chief executive officer at Notal Vision.</p> <p><strong>Disclosures:</strong> Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; g